Cargando…
Diabetes, bone and glucose-lowering agents: basic biology
Skeletal fragility often accompanies diabetes and does not appear to correlate with low bone mass or trauma severity in individuals with diabetes. Instead (and in contrast to those with osteoporotic bone disease), bone remodelling and bone turnover are compromised in both type 1 and type 2 diabetes,...
Autor principal: | Lecka-Czernik, Beata |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5487688/ https://www.ncbi.nlm.nih.gov/pubmed/28434032 http://dx.doi.org/10.1007/s00125-017-4269-4 |
Ejemplares similares
-
Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis
por: Lecka-Czernik, Beata
Publicado: (2010) -
PPARs and Bone Metabolism
por: Lecka-Czernik, Beata
Publicado: (2006) -
Resolving the Two “Bony” Faces of PPAR-γ
por: Lecka-Czernik, Beata, et al.
Publicado: (2006) -
Report From the 6(th) International Meeting on Bone Marrow Adiposity (BMA2020)
por: Scheller, Erica L., et al.
Publicado: (2021) -
Partial Agonist, Telmisartan, Maintains PPARγ Serine 112 Phosphorylation, and Does Not Affect Osteoblast Differentiation and Bone Mass
por: Kolli, Vipula, et al.
Publicado: (2014)